73%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
73%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
73%
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
73%
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Coloplast A-S (Class B)
Cerrado
546.2 0.18
Resumen
Variación precio
24h
Mínimo
541.2
Máximo
546.8
Ingresos | 70M 875M |
|---|---|
Ventas | 2M 7B |
P/B Media del Sector | 33.663 78.892 |
BPA | 3.88 |
Rentabilidad por dividendo | 4.24 |
Margen de beneficios | 12.572 |
Empleados | 16,744 |
EBITDA | 2B |
Recomendaciones | Neutral |
|---|---|
Estimación a 12 Meses | +11.86% upside |
Rentabilidad por dividendo Media del Sector | 4.24% 2.38% |
|---|
Capitalización Mercado | -14B 123B |
|---|---|
Apertura anterior | 546.02 |
Cierre anterior | 546.2 |
Coloplast A-S (Class B) Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Coloplast A-S (Class B) previsión
Precio Objetivo
By TipRanks
11.86% repunte
Estimación a 12 Meses
Media 901.38 DKK 11.86%
Máximo 1,056 DKK
Mínimo 720 DKK
De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Coloplast A-S (Class B) Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Coloplast A-S (Class B)
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.